

This listing of claims will replace all prior versions, and listings, of claims in the application:

DT04 Rec'd PCT/PTO 1 8 OCT 2004

**Listing of Claims:**

**Cancel Claims 1-171**

172. (Original) A method of detecting a pancreas cell, comprising:

contacting a sample comprising cells with a polynucleotide specific TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127 of claim 199 under conditions effective for said polynucleotide to hybridize specifically to said gene, and detecting specific hybridization.

173. (Original) A method of claim 172, wherein said detecting is performed by:

Northern blot analysis, polymerase chain reaction (PCR), reverse transcriptase PCR, RACE PCR, or *in situ* hybridization.

174. (Original) A method of detecting a pancreas cell, comprising:

contacting a sample comprising cells with a binding partner specific for a polypeptide coded for by TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127 of claim 199 under conditions effective for said binding partner bind specifically to said polypeptide, and detecting specific binding.

175. (Original) A method of claim 174, wherein said detecting is performed by:

immunocytochemistry, immunoprecipitation, or Western blot.

176. (Original) A method of delivering an agent to a pancreas cell, comprising:

contacting a pancreas with an agent coupled to binding partner specific for TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127 of claim 199, whereby said agent is delivered to said cell.

177. (Original) A method of claim 176, wherein the agent is a therapeutic agent or an imaging agent.

178. (Original) A method of claim 176, wherein the agent is cytotoxic.

179. (Original) A method of claim 176, wherein the binding partner is an antibody.

180. (Original) A method of modulating a pancreas, immune, or reticuloendothelial cell, comprising:

contacting said cell with an agent effective to modulate TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127, or the biological activity of a polypeptide encoded thereby, of claim 199, whereby the cell is modulated.

181. (Original) A method of assessing pancreas function, comprising:

detecting a polypeptide coded for by TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127 of claim 199, or fragments thereof, in a body fluid, whereby the amount of said polypeptide in said fluid is a measure of pancreas function.

182. (Original) A method of claim 181, wherein said detecting is performed using an antibody which is specific for said polypeptide.

183. (Original) A method of claim 181, wherein said detecting is performed by RIA, ELISA, or Western blot.

184. (Original) A method of expressing a heterologous polynucleotide in pancreas cells, comprising:

expressing a nucleic acid construct in pancreas cell, said construct comprising a promoter sequence operably linked to said heterologous polynucleotide, wherein said promoter sequence is selected SEQ ID NO 258, 261, 262, 265-267, 270-272, 275, 278, 279, 282-284, 287, 290-293, 296, 297, 300, 303, 306, 309-314, 317-320, 323-326, 329, 332-333, 336-338, 341, and 344.

185. (Original) A method of assessing a therapeutic or preventative intervention in a subject having a pancreas or lymphoid disease, comprising,

determining the expression levels of TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127, or a polypeptide encoded thereby, of claim 199 in a tissue sample comprising pancreas, lymphoid, or reticuloendothelial cells.

186. (Original) A method of claim 185, further comprising assessing the expression levels of a plurality of said genes or polypeptides.

187. (Original) A method for identifying an agent that modulates the expression of TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127, comprising,

contacting a pancreas, lymphoid, or reticuloendothelial cell, with a test agent under conditions effective for said test agent to modulate the expression of TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127, of claim 199, and determining whether said test agent modulates said gene.

188. (Original) A method of claim 187, wherein said agent is an antisense which is effective to inhibit translation of said gene.

189. (Original) A method for identifying an agent that modulates the expression of a polypeptide coded for by TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127, comprising,

contacting a polypeptide coded for by TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127 of claim 199, with a test agent under conditions effective for said test agent to modulate said polypeptide, and determining whether said test agent modulates said polypeptide.

190. (Original) A method of claim 189, wherein said test agent is an antibody.

#### Cancel Claims 191-197

198. (Original) A method of selecting a gene predominantly expressed in pancreas tissue from a database comprising polynucleotide and amino acid sequences for genes, comprising:

displaying, in a computer-readable medium, a polynucleotide sequence or polypeptide sequence for TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127, of claim 199, or complements to the polynucleotides sequence, wherein said displayed sequences have been retrieved from said database upon selection by a user.

199. (Original) A composition comprising genes and/or polypeptide which are expressed predominantly in pancreas tissue comprising:

TMD0077, TMD0233, TMD0256, TMD0258, TMD0267, TMD0271, TMD0290, TMD0530, TMD0574, TMD0608, TMD0639, TMD0645, TMD0674, TMD0675, TMD0677, TMD0726, TMD0727, TMD0739, TMD0753, TMD1111, and/or TMD1127.

200. (New) A method of treating pancreas cancer comprising,  
administering an antibody specific for TMD 0645 which is effective to treat the pancreas cancer.